Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,251 - 1,300 out of 12,335

Document Document Title
WO/2009/006620A1
Provided are methods of producing, and compositions comprising, isolated alpha (2→8) or (2→9) oligosialic acid derivatives bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exone...  
WO/2009/005382A2
The subject of the invention includes derivatives of nucleoside-5'-O-hypophosphates and their mono- and dithiohypophosphate analogues, in particular 5'-O-[β,β-dialkyl-(α- thiohypophosphate)]-, 5'-O -[β,β-dialkyl-(α,α-dithiohypopho...  
WO/2009/006478A2
The present disclosure describes 6-disubstituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the 6-disubstituted bicyclic nucleosides each comprise a 2'-...  
WO/2008/011406A3
The invention is directed to carbonate and carbamate prodrugs of thiazolo[4,5-J]pyrimidine compounds, whose metabolized parent compound has immunomodulatory activity. The invention also relates to the therapeutic use of such prodrugs and...  
WO2007070598A8
The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in...  
WO/2008/157319A1
Disclosed are compositions and methods for reducing the proliferation of ALL cancer cells through targeted interactions with ALL1 fusion proteins.  
WO/2008/099203A3
Reactions of isotopically enriched samples of elements selected from phosphorus, sulfur, selenium and/or tellurium involving the addition of atoms of the isotope to organic or inorganic molecules comprising use of an ionic liquid as a re...  
WO/2008/100447A3
The invention provides unsaturated phosphonates of Formula I or a tautomer or pharmaceutically accepatble salt thereof, as described herein, as well as pharmaceutical compositions comprising the compounds, and therapeutic methods compris...  
WO/2008/157438A1
Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The inven...  
WO/2008/157688A2
New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2'-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation duri...  
WO/2008/157751A2
The present invention provides substituted imidazoheterocyclic compounds having the structure of Formula (I) Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formul...  
WO/2008/154639A2
The current invention provides methods (e.g., large-scale processes) for the production of nucleotide sugars, which are modified with a polymeric modifying group, such as poly(alkylene oxide) moieties (e.g., poly(ethylene glycol) or poly...  
WO/2008/154401A2
Provided herein are saturated and unsaturated carbocyclic bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using these oligomeric compounds. The saturated and unsaturated carbocyclic bicyclic nucleosides are u...  
WO/2008/131062A3
There is provided processes for the preparation of capecitabine and intermediates thereof.  
WO/2008/154629A1
Myeloid differentiating agents can be used in the treatment of myeloid disorders.  
WO/2008/151024A1
Therapeutically active nucleosides and associated methods are provided. In one aspect, a nucleoside molecule having a general structural similar to ATP. Such nucleosides have a structure that allows binding to, and subsequent regulation ...  
WO/2008/150729A2
Provided herein are bicyeMc nucleosides comprising a substituted amino group in the bridge, oligomeric compounds having at least one of these bi cyclic nucleosides and methods of using the oligomeric compounds. The bicyclic nucleosides c...  
WO/2008/144980A1
The present invention relates to the preparation method and intermediates of capecitabine. The present invention provides a new synthesis route for capecitabine, in which doxifluridine is used as the starting material and capecitabine is...  
WO/2008/147454A1
An agent for inhibiting P-glycoproteins comprises a non-natural adenine ribose analog.  
WO/2008/144878A1
A modular process for organosolv fractionation of lignocellulosic feedstocks into component parts and further processing of said component parts into at least fuel-grade ethanol and four classes of lignin derivatives. The modular process...  
WO/2008/144970A1
The present invention provides a novel and highly stereoselective process for preparing gemcitabine, which is suitable for industrial production, wherein, it includes the following reactions. Additionally, the invention discloses the key...  
WO/2008/104408A3
This invention provides phosphate-modified nucleosides represented by the structural formula: wherein - B is a pyrimidine or purine base, or an analogue thereof, optionally substituted with one or two substituents independently selected ...  
WO/2008/145403A1
An intermediate (2) useful in making capecitabine can be formed without the use, or presence, of a silylation agent. formula (I):  
WO/2006/034190A3
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardi...  
WO/2008/144562A1
The present invention relates generally to programming of biomolecular self-assembly pathways and related methods and constructs. A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways for a wide varie...  
WO/2008/143667A1
Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.  
WO/2008/144472A1
The present invention provides compounds of the formula (I): C-Q-O-Si (R1)(R2)-N wherein C is a chromophore; Q is selected from the group consisting of optionally substituted aliphatic, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R...  
WO/2008/143846A1
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3'-azido-2',3'-dideoxy pur...  
WO/2008/142055A2
A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.  
WO/2008/021225A3
Polymorphic maize DNA loci useful for genotyping between at least two varieties of maize. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in maize DNA. Polymorphisms are usefu...  
WO/2008/144315A1
The invention provides a family of tethered nucleotide analogs useful in sequencing nucleic acids containing a homopolymer region comprising, for example, two or more base repeats, and to sequencing methods using such tethered nucleotide...  
WO/2008/080060A3
A compound having the formula (I): wherein R1 is H, HO, acyl-O, TOM-O, ACE-O, alkyl-O, orthoester, TBDMS-O, HSe, diselenide, or alkyl-Se, R2 is H, HO, acyl-O, TOM-O, ACE-O, CH3-Se, alkyl-O, TBDMS-O, TMS-O, HSe, diselenide, alkyl-Se, phos...  
WO/2008/141248A2
Aspects of the invention include 2 ' protected nucleoside monomers that are protected at the 2' site with thiocarbon protecting groups such as formula (I). Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, ...  
WO/2008/138389A1
The invention relates to a method of preparation of a quaternary amine having formula 2, by reacting an epoxide having formula 3, Formula 3 with an aliphatic tertiairy amine group in the presence of a suitable Lewis acid.  
WO/2008/137207A2
Disclosed are compounds that are AGT inactivators that include a folate residue, e.g., a compound of formula (I), wherein X1, X2, R1, and R2 are as described herein. Also disclosed is a pharmaceutical composition comprising a compound of...  
WO2008121941B1
A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. Particular pharmaceutical species are 6- amino-4-methyl-8-(beta.-D-ribofuranosyl)pyrrolo[4,...  
WO/2008/067002A3
Azole nucleosides represented by the formulae (I) and (II); wherein A = C or N B = C or N X = H; C1-C6 alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heterocyclo, halogen such as F, C1, Br and I; OH, NH2, NH-(C1-C6 alkyl, cyclo...  
WO/2008/133129A1
GW-328267, UK-432097, or a compound represented by the general formula (1) or a salt thereof, which is an adenosine A2A receptor agonist, exhibits an excellent ocular hypotensive effect in the test on decrease in ocular tension, and is t...  
WO/2008/037036A3
The present invention provides for oligonucleotide arrays wherein the oligonucleotides comprise six- membered sugar-ring nucleosides, especially tetrahydropyran nucleosides, more specifically altritol nucleosides. The present invention a...  
WO/2008/129530A1
Provided is a process for preparing gemcitabine or a salt thereof, which preferably includes selectively precipitating the β-anomer of a 3',5'-di-O-protected-N4-trimethylsilyl-2'-deoxy-2',2'-difluo rocytidine, removing the protecting gr...  
WO/2008/005542A3
A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administa...  
WO/2008/128428A1
The present invention provides 2, 6-dinitrogen-containing substituted purine compounds of formula (A) or their salts or their solvates or the solvates of their salts, as well as pharmaceutical compositions containing such compounds. The ...  
WO/2008/130902A1
The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).  
WO/2007/070598A3
The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in...  
WO/2008/128686A1
The present invention concerns modified mononucleotides and processes for their production wherein these nucleotides contain at least once the structure P = N - Acc in which Acc is an electron acceptor or an electron acceptor substituted...  
WO/2008/107771A3
The invention concerns new 2',3'-di-O-acyl-5-fluoronucleosides of formula (I) useful as intermediates in the preparation of 5'-deoxy-2',3'-di-O-acyl-5-fluoronucleosides.  
WO/2008/131062A2
There is provided processes for the preparation of capecitabine and intermediates thereof.  
WO/2008/128193A1
The invention provides polymers that include a biologically active molecule and methods for their use.  
WO/2008/082601A3
Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered ...  
WO/2007/146819A3
Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples.  

Matches 1,251 - 1,300 out of 12,335